Arvinas and Pfizer have shared preliminary outcomes from the Phase Ib segment of the TACTIVE-U sub-trial of vepdegestrant plus abemaciclib for treating individuals with locally advanced or ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

Herein we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. Abemaciclib+fulvestrant ...

The combination of imlunestrant and abemaciclib further enhanced PFS to 9.4 months, regardless of ESR1 mutation status. Consistent benefits were observed across subgroups, including those with ...

Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant–abemaciclib. Primary end points were investigator-assessed progression-free ...

This page includes links to articles highlighting the top breast cancer research published on Cancer Therapy Advisor in 2024.

Jhaveri and colleagues also evaluated imlunestrant in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) versus imlunestrant alone among all patients, and found that the combination ...

"The main purpose of this EMBER-3 trial was to evaluate the role of imlunestrant, a brain-penetrant oral SERD, as monotherapy or in combination with the CDK4/6 inhibitor, abemaciclib, in patients ...

Alpelisib, we ran into a lot of toxicities, but they were all alpelisib toxicities. So a lower dose will be tested in the next cohort with elacestrant. And then capivasertib [Truqap] is in the early ...

Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safe – Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical ...